Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.27 USD | -2.19% | -2.92% | -2.92% |
Financials (USD)
Sales 2024 * | 2.65B | Sales 2025 * | 2.92B | Capitalization | 12.3B |
---|---|---|---|---|---|
Net income 2024 * | 942M | Net income 2025 * | 1.1B | EV / Sales 2024 * | 6.82 x |
Net Debt 2024 * | 5.78B | Net Debt 2025 * | 6.04B | EV / Sales 2025 * | 6.27 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
11
x | Employees | - |
Yield 2024 * |
3.3% | Yield 2025 * |
3.58% | Free-Float | 85.52% |
Latest transcript on Royalty Pharma plc
1 day | -2.19% | ||
1 week | -2.92% | ||
Current month | -1.55% | ||
1 month | -2.22% | ||
3 months | -8.86% | ||
6 months | +2.52% | ||
Current year | -2.92% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 254 M€ | +10.97% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 27.27 | -2.19% | 1,906,556 |
24-05-16 | 27.88 | -1.17% | 3,013,309 |
24-05-15 | 28.21 | +0.50% | 1,906,709 |
24-05-14 | 28.07 | -1.09% | 2,239,812 |
24-05-13 | 28.38 | +1.03% | 2,033,673 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.92% | 12.3B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- RPRX Stock